Overview

• US precision oncology firm's Q1 net loss widened, missing analyst expectations

• Collaboration revenue for Q1 declined from prior quarter

• Company reported positive topline results from Phase 2/3 darovasertib trial in uveal melanoma

Outlook

• IDEAYA targets completion of NDA filing for darovasertib in H2 2026

• Company expects multiple clinical data updates and trial initiations in H2 2026

• IDEAYA maintains cash runway guidance into 2030

Result Drivers

• R&D EXPENSES - Higher research and development costs driven by increased clinical trial and personnel expenses to support pipeline programs

• G&A EXPENSES - General and administrative costs rose due to higher personnel expenses and commercial preparation for darovasertib

• PIPELINE INVESTMENT - Ongoing investment in clinical programs and pipeline expansion contributed to higher operating expenses

Company press release: ID:nPn4ftbGVa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Collaboration Revenue		$6.56 mln
Q1 EPS	Miss	-$1.11	-$0.99 (16 Analysts)
Q1 Net Income	Miss	-$98.54 mln	-$87.02 mln (13 Analysts)
Q1 Profit From Operations	Miss	-$108.54 mln	-$97.63 mln (14 Analysts)
Q1 Operating Expenses		$115.10 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for IDEAYA Biosciences Inc is $52.00, about 79.9% above its May 4 closing price of $28.90

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.